Copyright
©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Jan 7, 2014; 20(1): 214-218
Published online Jan 7, 2014. doi: 10.3748/wjg.v20.i1.214
Published online Jan 7, 2014. doi: 10.3748/wjg.v20.i1.214
Table 3 Patients requiring dose escalation within 12 mo of therapy initiation
| Years between diagnosis and therapy initiation | < 2 yr | ≥ 2 yr | ||
| On concurrent immunosuppressant therapy | No | Yes | No | Yes |
| Proportion of subjects needed dose escalation within 12 mo | 4/5 = 0.80 | 2/7 = 0.29 | 8/21 = 0.38 | 5/19 = 0.26 |
- Citation: Lam MC, Lee T, Atkinson K, Bressler B. Time of infliximab therapy initiation and dose escalation in Crohn’s disease. World J Gastroenterol 2014; 20(1): 214-218
- URL: https://www.wjgnet.com/1007-9327/full/v20/i1/214.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i1.214